Giant cell tumors of bone are benign but locally aggressive tumors. Typically diagnosed in individuals between the ages of 20 and 40 years, these tumors cause significant amounts of pain, and morbidity. Giant cell tumors of bone can be treated with an increased dosing regimen of denosumab, a monoclonal antibody tha...
Robyn Birch, F. Eltit, T. Ng et al.· Frontiers in Medicine· 0 citations
Postoperative AE’s are extremely relevant to the care of patients with MSD and impact both HRQoL and survival and a multivariate analysis demonstrated that age, smoking status, ECOG performance, prior radiotherapy, presence of multiple metastases at other sites, and multiple spine metastases were significant risk facto...
Andrew A. Hardigan, G. B. Brodano, Christina Griffoni et al.· Neuro-Oncology Advances· 0 citations
This is the first study defining a composite measure outcome in oncologic surgery for spinal metastases derived from an international group of surgeons and oncologists who treat patients for MSD and the OSCO-M will be useful for defining clinical success in patients undergoing treatment for MSD.
Andrew A. Hardigan, R. de la Garza Ramos, Michael H. Weber et al.· Neuro-Oncology Advances· 0 citations
The utility of ex vivo glioblastoma characterization is demonstrated, allowing decoding of tumor heterogeneity and clinical prognostication as well as providing a framework for deconvoluting the complex cancer phenotype.
Jay Hou, M. McMahon, Andrew Ni et al.· bioRxiv· 0 citations
Frailty and sarcopenia are common in the MSD population and multidimensional measurements of health that must be carefully considered with regard to treatment decision making, however, this review reinforces the lack of readily available tool to quantify both conditions and their effect on outcomes.
Eli Johnson, Mark A. Maclean, Antoinette J. Charles et al.· Neuro-Oncology Advances· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
